CN117467558A - Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof - Google Patents
Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof Download PDFInfo
- Publication number
- CN117467558A CN117467558A CN202310709086.4A CN202310709086A CN117467558A CN 117467558 A CN117467558 A CN 117467558A CN 202310709086 A CN202310709086 A CN 202310709086A CN 117467558 A CN117467558 A CN 117467558A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- influenza
- relieving
- immunity
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 48
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 47
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 47
- 206010022000 influenza Diseases 0.000 title claims abstract description 34
- 230000036039 immunity Effects 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 235000021107 fermented food Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 33
- 239000000243 solution Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 230000000242 pagocytic effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229960003752 oseltamivir Drugs 0.000 description 4
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 240000003049 Canavalia gladiata Species 0.000 description 1
- 235000010518 Canavalia gladiata Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- -1 azolium salt Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000005356 cow milk allergy Diseases 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of microbial engineering, and particularly discloses lactobacillus plantarum LZ026 for relieving influenza and improving immunity, wherein the lactobacillus plantarum LZ026 is preserved in China general microbiological culture collection center (CGMCC) No.22832, and the preservation date is 2021, 07 and 06 days. The invention also discloses application of lactobacillus plantarum LZ026 in relieving influenza and improving immunity. The lactobacillus plantarum LZ026 has remarkable antiviral and influenza relieving effects, and can improve the immunity of a human body, so that the lactobacillus plantarum LZ026 is applied to foods, medicines and health-care products, and has a huge application prospect.
Description
Technical Field
The invention relates to the technical field of microbial engineering, in particular to lactobacillus plantarum LZ026 with the effects of relieving influenza and improving immunity and application thereof.
Background
Influenza is often pandemic in autumn and winter, mainly induced by influenza virus. Influenza viruses can be classified into influenza a virus, influenza b virus and influenza c virus, and influenza suffered by humans is mainly caused by influenza a virus and influenza b virus. Viral infections are one of the important diseases that threaten human health worldwide and lead to human death. Therefore, the search for effective and safe methods for virus prevention and control has great application research value.
Currently, the world health organization considers annual vaccination in the early stages of influenza peak to be the most effective prophylactic means. At present, trivalent influenza vaccines which have been marketed are two types of inactivated influenza vaccines (TIV) and attenuated live vaccines (LAIV), consisting of 3 viruses, including 2 influenza a strains and 1 influenza b strain. The related influenza infection drug treatment mainly comprises two western medicines, one is neuraminidase inhibitors such as oseltamivir, zanamivir and peramivir, and the mechanism is that virus particles cannot invade human cells through glycoprotein neuraminidase acting on the surface of the virus; another class is M2 ion channel blockers such as amantadine and rimantadine, which act on the proton channel M2 protein to inhibit replication of influenza a virus by blocking its protein ion channel.
However, vaccine injection is not long-term effective in protecting the body from infection by the virus, and drug treatment has side effects on the central nervous system while killing the virus. Therefore, there is still a need for a drug or treatment regimen that can not only effectively protect the body from infection by influenza virus for a long time, but also alleviate some clinical conditions of influenza, and at the same time, does not bring side effects to the central nervous system of the patient.
Probiotics are active microorganisms that promote host health and are also a class of food-grade microorganisms that are considered to be safe for long periods of time. In recent years, a great deal of research shows that intestinal microorganisms play an important role in maintaining human health, meanwhile, probiotics have an important role in health in human intervention research, including improving acute diarrhea of children, relieving cow milk allergy and atopic dermatitis of children and relieving irritable bowel syndrome of human, and the probiotics can possibly influence intestinal mucosa, balance local microbiota by inhibiting the growth of pathogenic microorganisms, further enhance local and systemic immune responses, influenza caused by viruses can influence intestinal flora structure, and specific probiotics can effectively relieve the duration and severity of gastroenteritis of acute rotavirus. Therefore, starting from intestinal microorganisms, new drugs or new methods for preventing and treating influenza can be found, and the immunity of the organism is improved.
Disclosure of Invention
In order to solve the problems, the invention provides the lactobacillus plantarum LZ026 and the application thereof, which have remarkable antiviral and influenza relieving effects, can improve the immunity of human bodies, and have great application prospects when the lactobacillus plantarum LZ026 is applied to foods, medicines and health-care products.
One of the purposes of the invention is to provide lactobacillus plantarum LZ026 with the effects of relieving influenza and improving immunity, which has remarkable antiviral and influenza relieving effects, and can improve the immunity of human bodies.
The second object of the invention is to provide the application of lactobacillus plantarum LZ026 in foods, medicines and health care products.
In order to achieve the above-mentioned purpose, the invention provides a Lactobacillus plantarum LZ026 for alleviating influenza and enhancing immunity, which is isolated from the Carnis Sus Domestica of farmer, guizhou province, and is preserved in China general microbiological culture Collection center with the preservation number of CGMCC No.22832 and the preservation date of 2021, 07 and 06 days.
The invention also provides application of the lactobacillus plantarum LZ026 in improving the antibody level and T cell response of an organism.
The invention also provides an application of the lactobacillus plantarum LZ026 in relieving influenza.
The invention also provides application of the lactobacillus plantarum LZ026 in improving immunity.
The lactobacillus plantarum LZ026 is used for preparing products for relieving influenza and improving immunity, and the products comprise foods, medicines or health-care products.
Preferably, the viable bacterial count of Lactobacillus plantarum LZ026 in the product is not less than 1×10 7 CFU/mL。
Preferably, the food comprises solid beverage and fermented food, and the medicine comprises a medicine dressing containing lactobacillus plantarum LZ026 and a medicine carrier.
Preferably, the health-care product component also comprises a composition, wherein the composition comprises stachyose, lactobacillus rhamnosus, beta-glucan, vitamin C and collagen.
The lactobacillus plantarum LZ026 with the functions of relieving influenza and improving immunity and the application thereof have the advantages and positive effects that:
1. in the application of the lactobacillus plantarum LZ026 in health products, the lactobacillus plantarum LZ026 can improve the immunity of organisms through mutual cooperation with the composition.
2. According to the invention, the lactobacillus plantarum LZ026 product is taken, so that the specific immunity of the organism to influenza viruses is enhanced, the immune response of antibody level and T cells is improved, the viral load in the organism is reduced, and the influenza is effectively relieved.
The technical scheme of the invention is further described in detail through the drawings and the embodiments.
Drawings
FIG. 1 is a measurement result of viral load in rats in example 2 of the present invention;
FIG. 2 shows the results of the measurement of the concentration of specific antibodies in example 3 of the present invention.
Detailed Description
The technical scheme of the invention is further described below through the attached drawings and the embodiments.
Unless defined otherwise, technical or scientific terms used herein should be given the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs.
Preservation information
Lactobacillus plantarum LZ026 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.22832 and the preservation date of 2021, 07 and 06 days, and is classified and named as Lactobacillus plantarum Lactobacillus plantarum.
The following examples relate to the following media: MRS agar medium: 10g of peptone, 8g of beef extract powder, 4g of yeast extract powder, 20g of glucose, 1.08g of tween 80, 2g of dipotassium hydrogen phosphate (anhydrous), 5g of sodium acetate (anhydrous), 2g of diammonium hydrogen citrate (anhydrous), 0.2g of magnesium sulfate (anhydrous), 0.05g of magnesium sulfate (monohydrate), 0.5g of L-cysteine, 15g of agar and 1000mL of distilled water.
MRS liquid medium: 10g of peptone, 8g of beef extract powder, 4g of yeast extract powder, 20g of glucose, 1.08g of tween 80, 2g of dipotassium hydrogen phosphate (anhydrous), 5g of sodium acetate (anhydrous), 2g of diammonium hydrogen citrate (anhydrous), 0.2g of magnesium sulfate (anhydrous), 0.05g of magnesium sulfate (monohydrate), 0.5g of L-cysteine and 1000mL of distilled water.
EXAMPLE 1 isolation and identification of Lactobacillus plantarum
Collecting farmyard special sour meat in Zunyi city of Guizhou province as a sample, adding 5g sour meat sample into 15mL MRS liquid culture medium under aseptic condition, shaking uniformly, and enrichment culturing at 37deg.C for 24 hr; taking 1mL of bacterial liquid for gradient dilution, adding physiological saline to prepare 10 -6 To 10 -8 The concentration gradient bacterial suspension is coated and inoculated into MRS agar culture medium, and cultured for 48 hours at 37 ℃; according to colony characteristics of lactobacillus and pictures of reference related documents, selecting corresponding colonies to MRS agar culture medium for streak purification culture, then selecting single colonies to MRS liquid culture medium, and culturing at 37 ℃ for 48 hours to obtain single strain. The single strain is sent to a third party company for strain identification, and the obtained single strain is obtainedLactobacillus plantarum LZ026.
EXAMPLE 2 antiviral study of Lactobacillus plantarum LZ026
The female rats with good growth condition and weight of 30 g+/-5 g are randomly divided into 4 groups, a blank control group A, an influenza control group B, an oseltamivir drug treatment group C and a lactobacillus plantarum LZ026 treatment group D.
The rats were physically tested 3 days before the experiment to ensure that the growth conditions of the rats remained consistent.
On the 1 st day of the experiment, the influenza virus is detoxified for the rats of the B group, the C group and the D group, and the principle of small quantity and multiple times is adopted, namely once every 2 hours, 30 minutes are adopted, and the period lasts for 12 hours. The viral load in rats was then measured every 6 hours for a total of 2 times and recorded.
On day 2 of the experiment, oseltamivir was administered to group C rats for treatment, and group D rats were given the same dose of 1×10 8 CFU lactobacillus plantarum LZ026 dilutions were gavaged for treatment, and group a and group B rats were gavaged daily with the same dose of saline. The principle of a small number of times is adopted, namely once every 6 hours, and the total is 2 times. A. After B, C, D groups were dosed for 12 hours, the viral load in rats was determined using real-time quantitative fluorescent PCR or enzyme-linked immunosorbent assay, once every 6 hours for a total of 2 times, and recorded.
On experiment 3-5 days, A, B, C, D groups were dosed daily, viral loads in rats were determined and recorded in the same manner as on experiment 2 day.
As shown in fig. 1, the decrease in influenza virus load was more remarkable in group C rats at 3-5 days, indicating that oseltamivir can inhibit replication of influenza virus and effectively alleviate influenza. Group A is a blank control group, the viral load in the rat body is always at a lower level, group B is an influenza control group, the rat completely relies on autoimmunity to relieve influenza, and the viral load is still maintained at a higher level in 3-5 days. The group D is a lactobacillus plantarum treatment group, the reduction of the viral load in the rat body is obvious in 3-5 days, but the reduction trend is slower than that of the group C, which proves that the lactobacillus plantarum can inhibit the replication of influenza viruses to a certain extent and effectively relieve influenza.
EXAMPLE 3 study of enhanced antibody levels of Lactobacillus plantarum LZ026
The male rats with good growth condition and weight of 20 g+/-5 g are randomly divided into A, B, C groups. A. B, C three groups of rats are subjected to influenza virus challenge, after influenza symptoms appear in the rats, vaccine injection is carried out until the rats are recovered, the rats are continuously fed for 30 days, 0.2mL of physiological saline is injected into the group A rats each day within 30 days, and 0.2mL of 1X 10 is injected into the group B rats each day 8 CFU lactobacillus plantarum LZ026 dilutions, group C rats were untreated. After 30 days, two groups of A, B rats were subjected to the same influenza virus challenge, and A, B groups of rats were recorded for time to onset, and the results are shown in table 1. A. The in vivo antibody level was measured 6 hours after the onset of the disease in the two groups B of rats, and the in vivo antibody level was measured simultaneously in the group C of rats, and the results are shown in fig. 2.
Table 1 time to onset of two groups of rats 1A, B
As shown in Table 1, the onset time of the two groups of rats in B is obviously longer than that of the rats in A, which indicates that the rats in B have a certain immunity to influenza, thereby indicating that the Lactobacillus plantarum LZ026 can effectively improve the immunity of the rats.
As can be seen from fig. 2, compared with group C, the specific antibody level in vivo was significantly increased after 6h of onset in the A, B two groups of rats, which indicates that lactobacillus plantarum LZ026 can significantly increase the concentration of the specific antibody in the secondary immunization process and improve the immunity of the organism.
EXAMPLE 4 study of Lactobacillus plantarum LZ026 for increasing immunity
The experimental subjects are inbred female mice, 18-22g, 10-15 mice per group, A, B mice per group, and group A mice are fed with 1×10 mice 8 CFU dilution of lactobacillus plantarum LZ026, group B was not fed lactobacillus plantarum LZ026 as a blank, the other feeding conditions were identical, and the following experiments were performed on two groups of A, B mice after 30 days.
ConA-induced mouse spleen lymphocyte transformation assay
When T lymphocytes are stimulated by ConA, proliferation reaction of the blast cells occurs, and MTT (a faint yellow azolium salt) can be decomposed into blue-violet crystals by mitochondrial hydrolase in living cells, especially in proliferation cells, and the optical density value of the MTT can reflect the proliferation condition of the cells. This principle was applied to determine lymphocyte proliferation response.
a. Instrument and materials
RPMI1640 cell culture solution, calf serum, 2-mercaptoethanol (2-ME), penicillin, streptomycin, canavalia gladiata (ConA), hydrochloric acid, isopropanol, MTT, hank's solution, PBS buffer (pH 7.2-7.4)
Gauze or 200 mesh screen, 24-well culture plate, 96-well culture plate (flat bottom), surgical instrument, carbon dioxide incubator, enzyme-labeled instrument, 721 spectrophotometer, ultra-clean bench, autoclave, sterile filter.
b. Experimental procedure
(1) Reagent preparation
Complete culture RPMI1640 medium was sterilized by filtration, and 10% calf serum, 1% glutamine (200 mmol/L), penicillin (100U/mL), streptomycin (100. Mu.g/L) and 5X 10 were added before use -5 The pH of the 2-mercaptoethanol solution is adjusted to 7.0-7.2 by using sterile 1mol/L HCl or 1mol/L NaOH, namely the complete culture solution.
The ConA solution was prepared into a 100. Mu.g/mL solution with double distilled water, filtered and sterilized, and stored in a low temperature refrigerator (-20 ℃).
The pH of the sterile Hank's solution was adjusted to 7.2-7.4 with 3.5% sterile NaHCO3 prior to use.
MTT solution 5mg of MTT was dissolved in 1mL of PBS pH7.2 and used.
To 96mL of isopropanol, 4mL of 1mol/L HCl was added and the mixture was prepared immediately before use.
(2) Spleen cell suspension preparation
The spleen was aseptically removed and placed in a dish containing an appropriate amount of asepsis Hank's solution, and the spleen was gently crushed with forceps to prepare a single cell suspension. The spleen was either filtered through a 200 mesh screen or ground with 4 layers of gauze, washed 2 times with Hank's solution and centrifuged for 10min (1000 r/min) each. Then suspending the cells in 1mL of complete culture solution, and counting the number of living cells by using the dyeing of the typhoonAbove 95%) and adjusting cell concentration to 3×10 6 And each mL.
(3) Lymphocyte proliferation response
Each spleen cell suspension was added to a 24-well plate in two wells, 1mL each, with 75. Mu.LConA solution (equivalent to 7.5. Mu.g/mL) added to one well and 5% CO placed in the other as a control 2 ，37℃CO 2 Culturing in incubator for 72 hr. 4h before the end of the culture, 0.7mL of supernatant was gently aspirated from each well, 0.7mL of RPMI1640 medium containing no calf serum was added, and 50. Mu.L/well of MTT (5 mg/mL) was added at the same time, and the culture was continued for 4h. After the cultivation is finished, 1mL of acidic isopropanol is added into each hole, and the mixture is blown and evenly mixed, so that the purple crystals are completely dissolved. The resulting mixture was dispensed into 96-well plates, 3 wells were formed in parallel, and the optical density was measured at 570nm using an enzyme-labeled instrument, and the results are shown in Table 2.
TABLE 2
c. Data processing and result determination
The difference of the optical density of the tested sample group is obviously higher than that of the control group, and the positive result of the experiment can be judged. From table 2, the difference in optical density of group a is significantly higher than that of group B, indicating that the proliferation ability of group a mouse lymphocytes is stronger and the immunity is significantly improved.
(II) antibody-producing cell detection
The Sheep Red Blood Cell (SRBC) -immunized mouse spleen cell suspension was mixed with a quantity of SRBC to lyse SRBC around the antibody-secreting spleen cells in the presence of complement, forming macroscopic plaques. The number of lysoplaques may reflect the number of antibody-producing cells. The principle is applied to detect antibody-producing cells.
a. Instrument and materials
Carbon dioxide incubator, thermostatic water bath, centrifuge, surgical instrument, slide frame, 200 mesh screen, SRBC, complement (guinea pig serum), hank's solution, RPMI1640 culture solution, SA buffer solution, agarose.
b. Experimental procedure
(1) SRBC sheep jugular vein blood is taken, sheep blood is put into a sterilizing conical flask with glass beads and is rocked towards one direction to be defibrinated, and the sheep blood is put into a refrigerator at 4 ℃ to be stored for standby, and can be stored for 2 weeks.
(2) Preparation of complement-collected guinea pig blood, separation of serum (mixed serum of at least 5 guinea pigs), addition of 1mL of the packed SRBC to 5mL of guinea pig serum, standing at 4 ℃ for 30min, frequent shaking, centrifugation to obtain supernatant, sub-packaging, and storage at-70 ℃. When in use, SA buffer is used according to the following formula 1:8-15 dilution.
(3) The slide film is coated with a thin layer of agarose (0.5 g agarose plus double distilled water to 100 mL) on a clean slide, and the slide film can be preserved for a long time for standby after being dried.
(4) Defibrinated sheep blood was collected from immunized animals, washed 3 times with physiological saline, centrifuged (2000 r/min) for 10min each time, and cells were counted, and each mouse was intraperitoneally or intravenously injected with SRBC 5X 10 7 ～2×10 8 And each. The packed SRBC may also be formulated as a 2% (v/v) cell suspension in normal saline, and each mouse may be intraperitoneally injected with 0.2mL.
(5) Spleen cell suspension preparation
Killing cervical dislocation of mice after SRBC immunization for 4-5 days, taking out spleen, placing in a small plate containing Hank's liquid, lightly grinding spleen to prepare cell suspension, filtering with 200 mesh screen, or grinding spleen with 4 layers of gauze, centrifuging (1000 r/min) for 10min, washing with Hank's liquid for 2 times, finally suspending cells in 5mLRPMI1640 culture solution, counting cells, and adjusting cell concentration to 5×10 6 And each mL. Cells may also be suspended in 8ml of LHank's solution.
(6) Determination of plaque
Heating and dissolving surface culture medium (1 g agarose and double distilled water to 100 mL), placing in 45-50deg.C water bath, holding, mixing with equal amount of Hank's solution with pH of 7.2-7.4 and 2 times concentration, subpackaging into small test tubes with 0.5mL each, adding 50 μl of 10% SRBC (v/v prepared with SA buffer solution) into the tubes, and adding 20 μl of spleen cell suspension (5×10) 6 individual/mL) or 25 μl of spleen cell suspension, rapidly mixed, poured onto a thin layer of brushed agaroseAnd (3) making parallel sheets on the glass slide, placing the glass slide on a sheet frame after agar is solidified, placing the glass slide in a carbon dioxide incubator for incubation for 1-1.5 h, then adding complement diluted by SA buffer solution (1:8) into a groove of the glass slide frame, and counting the number of hemolysis plaques after continuous incubation for 1-1.5 h, wherein the result is shown in Table 3.
TABLE 3 Table 3
c. Data processing and result determination
By plaque count/10 5 The number of plaques in the sample group is significantly higher than that in the control group, as indicated by spleen cells or plaque number/whole spleen cells, and the positive result of the experiment can be judged. As can be seen from table 3, the number of plaques in group a was significantly higher than that in group B, indicating that the number of antibody-producing cells in group a was large, the number of antibodies produced was large, and the immunity was significantly improved.
(III) experiments on chicken erythrocytes engulfed by macrophages in abdominal cavity of mice
By utilizing the characteristic that macrophages have adhesion to smooth surfaces such as glass surfaces, abdominal cavity liquid containing the macrophages is dripped on a glass slide, chicken erythrocytes are added, after a certain period of incubation, non-adhered cells are washed away, the fixed dyeing is carried out, and the phagocytic rate and the phagocytic index of the macrophages which phagocytize the chicken erythrocytes are counted under a microscope, so that the phagocytic capacity of the macrophages is judged. This principle was applied to determine the phagocytic capacity of mouse macrophages.
a. Instrument and materials:
microscope, 37 ℃ incubator, counter, surgical instrument set, syringe, dropper, rubber head suction tube, ear suction ball, glass slide, staining tank, test tube
(1) Slide processing
The repeatedly used glass slide is soaked in the washing liquid, washed and dried, and then soaked in alcohol overnight. Before use, the product is wiped or dried by gauze, otherwise macrophage adhesion and microscopic examination are affected. The slides were marked and each slide was marked with two circles (the circles must be totally closed or the liquid would flow out) with 3% agar (formulation see reagent section) and left to dry.
(2) Enamel or plastic box: the gauze is wet with warm water and is put into incubator for standby, and the gauze is flat.
(3) Reagent preparation method
Preparation of agar:
3g of agar is taken, 100mL of water is added, the mixture is heated and boiled until the mixture is transparent, and 1 to 2 drops of 1 percent bromocresol purple indicator are added.
The preparation method of the PBS buffer solution comprises the following steps:
KH 2 PO 4 6.66g，Na 2 HPO 4 ·12H 2 6.38g of O, and the reagent is dissolved in 1000mL of distilled water to adjust the pH value to 7.2.
Chicken erythrocyte suspension:
before experiment, the jugular vein or arterial blood of chicken is taken and placed in a triangular flask containing glass beads (about 20), and is continuously and fully shaken along one direction for 5-10 min, fibrin is removed, and the chicken is preserved in a refrigerator at 4 ℃. Washing 3 times with physiological saline, centrifuging for 10min at 1500r/min, discarding supernatant, and preparing into 1% erythrocyte suspension with Hank's solution according to hematocrit.
Giemsa dye liquor:
giemsa dye 0.5g, neutral glycerol 33mL, methanol 33mL was taken. Firstly, putting the Giemsa dye into a clean mortar, adding glycerol, grinding for a while, pouring into a brown bottle, placing into a water bath box at 55-60 ℃ for 2 hours, continuously shaking, adding methanol, shaking, and preserving for later use.
II, diluting the giemsa staining solution: when in use, 8 parts of buffer solution with pH of 6.8 and 1 part of stock solution of the giemsa staining solution are used to obtain the application solution.
Giemsa dye liquor decolorization solution: the preparation method comprises the following steps: methanol 20mL and distilled water 80mL. Mixing and adding 2NHCl 2 And (5) dripping.
b. Experimental procedure
(1) Activation of mouse macrophages: each mouse was intraperitoneally injected with 0.2mL of 2% packed sheep red blood cells 4 days prior to the experiment. Mice were sacrificed by cervical dislocation, 4mL of Hank's solution with calf serum was injected intraperitoneally, and the abdomen was gently rubbed 20 times to sufficiently wash out macrophages in the abdomen, then the abdominal wall was cut to open a small opening, and 2mL of the peritoneal wash solution was sucked into a test tube (or a syringe) with a rubber head pipette.
(2) 0.5mL of the abdominal cavity washing liquid is sucked by a 1mL sample applicator, added into a test tube containing 0.5mL of 1% chicken red blood cell suspension, and uniformly mixed. 0.5mL of the mixture was aspirated with a syringe (containing a large needle) and added to the agar ring of the slide. The incubator is placed in a incubator for 15 to 20 minutes at 37 ℃. After the incubation, the non-adherent cells were washed out with physiological saline, fixed in methanol for 1 min, and stained with Giemsa for 15 min. Washing with distilled water, air drying, and counting phagocytosis rate and phagocytosis index with 40×microscope. The phagocytic rate is the percentage of macrophages that engulf chicken erythrocytes per 100 macrophages; the phagocytic index is the average number of chicken erythrocytes phagocytosed by each macrophage, and the experimental results are shown in table 4.
TABLE 4 Table 4
| Phagocytosis rate (%) | Phagocytic index (%) | |
| Group A (Experimental group) | 45.82±1.78 | 87.36±5.14 |
| Group B (control group) | 37.49±2.05 | 76.92±4.81 |
c. Data processing and result determination
The phagocytic percentage or index of the tested sample group is compared with that of the control group, the difference is significant, and the test result can be judged to be positive. As shown in table 4, the phagocytic rate and phagocytic index of group a were significantly higher than those of group B, indicating that group a mice had strong phagocytic ability and significantly improved immunity.
Therefore, the lactobacillus plantarum LZ026 with the effects of relieving influenza and improving immunity has remarkable antiviral and influenza relieving effects, and can improve the immunity of a human body, so that the lactobacillus plantarum LZ026 can be applied to foods, medicines and health-care products, and has a huge application prospect.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention and not for limiting it, and although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that: the technical scheme of the invention can be modified or replaced by the same, and the modified technical scheme cannot deviate from the spirit and scope of the technical scheme of the invention.
Claims (8)
1. Lactobacillus plantarum LZ026, characterized in that: the lactobacillus plantarum LZ026 is separated from the special sour meat of farmhouse in Zunyi city of Guizhou province and is preserved in China general microbiological culture Collection center with the preservation number of CGMCC No.22832 and the preservation date of 2021, 07 and 06 days.
2. Use of lactobacillus plantarum LZ026 according to claim 1 for increasing body antibody levels and T cell responses.
3. Use of lactobacillus plantarum LZ026 according to claim 1 for alleviating influenza.
4. Use of lactobacillus plantarum LZ026 according to claim 1 for increasing immunity.
5. Use according to any one of claims 3-4, characterized in that: the lactobacillus plantarum LZ026 is used for preparing products for relieving influenza and improving immunity, and the products comprise foods, medicines or health-care products.
6. The use according to claim 5, characterized in that: the viable bacteria amount of Lactobacillus plantarum LZ026 in the product is not less than 1×10 7 CFU/mL。
7. The use according to claim 5, characterized in that: the food comprises solid beverage and fermented food, and the medicine comprises medicine dressing containing lactobacillus plantarum LZ026 and medicine carrier.
8. The use according to claim 5, characterized in that: the health care product also comprises a composition, wherein the composition comprises stachyose, lactobacillus rhamnosus, beta-glucan, vitamin C and collagen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310709086.4A CN117467558A (en) | 2023-06-15 | 2023-06-15 | Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310709086.4A CN117467558A (en) | 2023-06-15 | 2023-06-15 | Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117467558A true CN117467558A (en) | 2024-01-30 |
Family
ID=89626314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310709086.4A Pending CN117467558A (en) | 2023-06-15 | 2023-06-15 | Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117467558A (en) |
-
2023
- 2023-06-15 CN CN202310709086.4A patent/CN117467558A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4317411A1 (en) | Lactobacillus rhamnosus, ferment lysate for regulating skin microecology, preparation method, and application | |
| KR20210088408A (en) | Lactobacillus Plantarum and uses thereof | |
| CN113142301A (en) | Dairy product capable of improving immunity of organism and preparation method thereof | |
| CN113616674A (en) | Application of extracellular vesicle with anti-inflammatory effect | |
| CN104258386B (en) | A kind of mink viral enteritis inactivated vaccine-canine distemper live vaccine combination | |
| CN111019858B (en) | Feeding bacillus licheniformis for inhibiting bacterial biofilm formation and application thereof | |
| CN111662870A (en) | Application of BCG polysaccharide nucleic acid in CIK cell in-vitro culture and preparation of tumor medicine | |
| CN115161348A (en) | Multi-effect metabiotic composition | |
| CN104611274A (en) | Haemophilus parasuis and application thereof | |
| CN112675203A (en) | Application of cell-derived exosome in preparation of biological preparation for treating asthma and/or pulmonary fibrosis | |
| CN117467558A (en) | Lactobacillus plantarum LZ026 capable of relieving influenza and improving immunity and application thereof | |
| CN114921351B (en) | Pichia pastoris DPUY-F1 with probiotics function and application thereof in relieving colonitis symptoms | |
| CN109010814A (en) | The production method of haemophilus parasuis and mycoplasma hyopneumoniae bivalent inactivated vaccine | |
| CN114129600A (en) | Novel application of composite probiotic preparation in anti-inflammatory product | |
| CN114042153B (en) | Milk cow mastitis multi-linked inactivated vaccine and preparation method and application thereof | |
| UA121358C2 (en) | INACTIVATED STAFFILOCOCCAL LIQUID VACCINE, METHOD OF PREPARATION AND METHOD OF TREATMENT AND PREVENTION BY IT | |
| Evans | The effect of hemolytic streptococci and their products on leucocytes | |
| CN113881633B (en) | Culture medium and method for in-vitro dry amplification of umbilical cord blood hematopoietic stem cells | |
| CN109401992B (en) | Pseudomonas aeruginosa for high-yield endotoxin protein and application thereof | |
| CN116479056A (en) | Peptide, peptide essence and application thereof in medicine for treating skin burn and scald | |
| CN118252859A (en) | Use of bacterial metabolites in colorectal cancer prevention or treatment | |
| CN116785237A (en) | Compound gentamicin injection and preparation method and application thereof | |
| CN116350773A (en) | Vaccine for hand-foot-mouth disease and preparation method and application thereof | |
| CN116350765A (en) | Vaccine for hand-foot-mouth disease and preparation method and application thereof | |
| CN118667890A (en) | Probiotics metazoan capable of promoting growth of vaginal probiotics and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |